Nesrin MOĞULKOÇ BISHOP
Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Göğüs Hastalıkları Anabilim Dalı
Araştırma alanları: Sağlık Bilimleri, Tıp, Dahili Tıp Bilimleri, Göğüs Hastalıkları ve Allerji, Kardiyoloji, İç Hastalıkları, Yoğun Bakım, Sosyal ve Beşeri Bilimler, Sosyoloji, Aile Hekimliği
Yayınlar
- Multiscale mapping of venous remodelling in idiopathic pulmonary fibrosis (2026)
- Statin use and its implications on survival and disease progression in the European MultiPartner idiopathic pulmonary fibrosis registry (EMPIRE) (2026)
- Oral Nalbuphine in Idiopathic Pulmonary Fibrosis–Associated Cough (2026)
- “Good health” and care needs in idiopathic pulmonary fibrosis/progressive pulmonary fibrosis: the COCOS-IPF patient-led European focus groups (2026)
- Safety and efficacy of namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung): a randomised, double-blinded, multicentre, phase 2 study (2026)
- Adverse side-effects of antifibrotic drugs in idiopathic pulmonary fibrosis—clarification of several points (2026)
- Pulmonary Alveolar Proteinosis in Greece–Türkiye–Cyprus: Answers in a Real‐Life Comparison (2026)
- Person-centred health outcomes in the routine care for people with progressive pulmonary fibrosis: the COCOS-IPF project’s European survey on healthcare professionals’ views and practices (2025)
- Risk factors and management of lung cancer in idiopathic pulmonary fibrosis: A comprehensive review. (2025)
- Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (2025)
- Tube2FEM: a general-purpose highly automated pipeline for flow-related processes in (embedded) tubular objects (2025)
- The COCOS-IPF Core Outcome Set for IPF/PPF Care: A Mixed-Method Multi-Perspective Approach (2025)
- Identifying outcome domains to establish a core outcome set for progressive pulmonary fibrosis: a scoping review (2025)
- Identifying outcome domains to establish a core outcome set for progressive pulmonary fibrosis: a scoping review (2025)
- Adverse side-effects of antifibrotic drugs and outcome of treatment in idiopathic pulmonary fibrosis (2025)
- Modelling of Overall Survival of IPF Patients With Different Phenotypes Treated With Nintedanib (2025)
- Analysis of treatment efficacy, tolerability, and survival of patients receiving antifibrotic therapy for progressive nonidiopathic pulmonary fibrosis (2025)
- Childhood interstitial lung disease survivors in adulthood: a European collaborative study (2025)
- Person-centred health outcomes in the routine care for people with progressive pulmonary fibrosis: the COCOS-IPF project’s European survey on healthcare professionals’ views and practices (2025)
- Lung Transplantation in Idiopathic Pulmonary Fibrosis Patients in the European MultiPartner IPF Registry: Challenges for Health Equity (2025)
- Diagnosis and Treatment Patterns of Chronic Thromboembolic Pulmonary Hypertension in Russia, Kazakhstan, Turkey, Lebanon, and Saudi Arabia: A Registry Study (2024)
- İdiyopatik Pulmoner Fibroziste Seri Solunum Fonksiyon Testlerinin Prognozu Belirlemedeki Önemi Retrospektif Analiz (2024)
- Lung cancer in patients with pulmonary fibrosis: characteristics features and prognosis. (2024)
- Health outcomes in IPF and PPF: European survey on healthcare professionals' views and practices (2024)
- High-resolution CT phenotypes in pulmonary sarcoidosis: a multinational Delphi consensus study (2024)
- Evaluation of automated airway morphological quantification for assessing fibrosing lung disease (2024)
- Short- and long-term clinical outcomes of nintedanib therapy in IPF patients with different phenotypes: A retrospective registry-based study (2024)
- Phase 2, Double-Blind, Placebo-controlled Trial of a c-Jun N-Terminal Kinase Inhibitor in Idiopathic Pulmonary Fibrosis (2024)
- Interpolation-split: a data-centric deep learning approach with big interpolated data to boost airway segmentation performance (2024)
- Diagnosis and Treatment Patterns of Chronic Thromboembolic Pulmonary Hypertension in Russia, Kazakhstan, Turkey, Lebanon, and Saudi Arabia: A Registry Study (2024)
- A modified Delphi exercise in physician-perceived risk factors for drug-induced pneumotoxicity in patients with rheumatological disease (2024)
- Interpolation-split: a data-centric deep learning approach with big interpolated data to boost airway segmentation performance (2024)
- IPF DIŞI PROGRESIF PULMONER FIBROZIS (PPF) HASTALARINDA ANTIFIBROTIKLERE İLIŞKIN ÇOK MERKEZLI GERÇEK YAŞAM VERILERI (2024)
- Multicenter real-world data of antifibrotics in non-IPF progressive pulmonary fibrosis (PPF) patients (2024)
- Inspiratory Crackles in Idiopathic Pulmonary Fibrosis – Friend or Foe for Early Diagnosis? (2024)
- Tube2FEM: a general-purpose highly-automated pipeline for flow related processes in (embedded) tubular objects (2024)
- Automated airway quantification associates with mortality in idiopathic pulmonary fibrosis (2023)
- Could Heart Rate Variability Serve as a Prognostic Factor in Patients with Pulmonary Hypertension? A Single-center Pilot Study (2023)
- Reduced CT-derived erector spinae muscle area: a poor prognostic factor for short- and long-term outcomes in idiopathic pulmonary fibrosis patients (2023)
- Idiopathic Pulmonary Fibrosis Is Associated with Common Genetic Variants and Limited Rare Variants (2023)
- Pulmonary Hypertension (2023)
- İDİYOPATİK PULMONER FİBROZİSLİ HASTALARDA BT DEN ÖLÇÜLEN EREKTÖR SPİNA KAS ALANI İLE HASTALIK PROGNOZU ARASINDAKİ İLİŞKİ (2023)
- Delineating associations of progressive pleuroparenchymal fibroelastosis in patients with pulmonary fibrosis (2023)
- Could Impedance Cardiography be a Non-Invasive Alternative Method of Measuring Cardiac Output in Patients with Pulmonary Hypertension? (2023)
- Mortality surrogates in combined pulmonary fibrosis and emphysema (2023)
- The Impact of Switching to a Second Antifibrotic in Patients With Idiopathic Pulmonary Fibrosis: A Retrospective Multicentre Study From the EMPIRE Registry (2023)
- Automated airway quantification associates with mortality in idiopathic pulmonary fibrosis (2023)
- Mortality surrogates in combined pulmonary fibrosis and emphysema (2023)
- Long-term effect of nintedanib treatment in 11 countries of Europe and Asia (2022)
- Survival and lung function decline in patients with definite, probable and possible idiopathic pulmonary fibrosis treated with pirfenidone (2022)
- Lung cancer in patients with idiopathic pulmonary fibrosis: A retrospective multicentre study in Europe (2022)
- Temporal progression of mediastinal lymphadenopathy in idiopathic pulmonary fibrosis (2022)
- Prognostic Imaging Biomarker Discovery in Survival Analysis for Idiopathic Pulmonary Fibrosis (2022)
- Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial) (2022)
- Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: the EMPIRE registry study (2022)
- Essential Features of an Interstitial Lung Disease Multidisciplinary Meeting An International Delphi Survey (2022)
- Lung cancer in patients with fibrosing interstitial lung diseases: an overview of current knowledge and challenges (2022)
- Airway inter-tapering and tortuosity predict mortality in idiopathic pulmonary fibrosis (2022)
- Prognostic Imaging Biomarker Discovery in Survival Analysis for Idiopathic Pulmonary Fibrosis (2022)
- Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial (2021)
- Mortality in combined pulmonary fibrosis and emphysema patients is determined by the sum of pulmonary fibrosis and emphysema (2021)
- Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial (2021)
- Akuttan Kroniğe Pulmoner Tromboemboli (2021)
- Mortality in combined pulmonary fibrosis and emphysema patients is determined by the sum of pulmonary fibrosis and emphysema (2021)
- Differences in Baseline Characteristics and Access to Treatment of Newly Diagnosed Patients With IPF in the EMPIRE Countries (2021)
- Pleuroparenchymal fibroelastosis in idiopathic pulmonary fibrosis: Survival analysis using visual and computer-based computed tomography assessment (2021)
- Evaluation of Patients with Fibrotic Interstitial Lung Disease: Preliminary results from the Turk-UIP Study (2021)
- Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here? (2021)
- Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study (2021)
- Development and Validation of a Clinical Diagnostic Scoring System for the Diagnosis of Idiopathic Pulmonary Fibrosis (2021)
- Pirfenidone Effectiveness in Idiopathic Pulmonary Fibrosis with Different Radiologic Patterns (2020)
- Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome (2020)
- The association between white blood cell count and outcomes in patients with idiopathic pulmonary fibrosis (2020)
- Right ventricular function in patients with pulmonary arterial hypertension associated with congenital heart disease with repaired and unrepaired defects correlation of speckle tracking, conventional echocardiography and clinical parameters (2020)
- Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE (2020)
- The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey. International survey and call for consensus (2020)
- Correlation of response to antifibrotic treatment with adverse events to antifibrotic drugs in IPF patients from the real-world EMPIRE registry (2020)
- Pirfenidone Effectiveness in Idiopathic Pulmonary Fibrosis with Different Radiologic Patterns (2020)
- Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE (2020)
- Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome (2020)
- The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis (2020)
- Assessment of right ventricular function in patients with pulmonary arterial hypertension-congenital heart disease and repaired and unrepaired defects: Correlation among speckle tracking, conventional echocardiography, and clinical parameters (2020)
- Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis (2020)
- The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey: international survey and call for consensus (2020)
- The effect of metformin on clinically relevant outcomes in 3,144 IPF patients from the EMPIRE registry (2020)
- The association between white blood cell count and outcomes in patients with idiopathic pulmonary fibrosis (2020)
- Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome. (2019)
- Differences between ANCA positive and negative lung fibrosis cases without vasculitis (2019)
- Baseline Characteristics of All Patients Randomized in a Phase IIb Trial of Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis and Risk of Pulmonary Hypertension (2019)
- Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study (2019)
- Differences between ANCA positive and negative lung fibrosis cases without vasculitis (2019)
- Long-term overall survival and progression-free survival in idiopathic pulmonary fibrosis treated by pirfenidone or nintedanib or their switch. Real world data from the EMPIRE registry (2019)
- Long-term overall survival and progression-free survival in idiopathic pulmonary fibrosis treated by pirfenidon or nintedanib or their switch. Real world data from the EMPIRE registry. (2019)
- Kronik Hipersensitivite Pnömonisinin Radyolojik Bulguları (2019)
- Differences between ANCA positive and negative lung fibrosis cases without vasculitis (2019)
- Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis (2019)
- Baseline Characteristics of All Patients Randomized in a Phase IIb Trial of Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis and Risk of Pulmonary Hypertension (2019)
- Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study (2019)
- Long-term overall survival and progression-free survival in idiopathic pulmonary fibrosis treated by pirfenidone or nintedanib or their switch. Real world data from the EMPIRE registry (2019)
- Long-term overall survival and progression-free survival in idiopathic pulmonary fibrosis treated by pirfenidon or nintedanib or their switch. Real world data from the EMPIRE registry. (2019)